Fortress Biotech Non-GAAP EPS of -$0.10 misses by $0.03, revenue of $18.89M misses by $4.29M

• Fortress Biotech press release (NASDAQ:FBIO): Q2 Non-GAAP EPS of -$0.10 misses by $0.03.
• Revenue of $18.89M (+5.9% Y/Y) misses by $4.29M.
• "In 2023, we expect to enroll the first patient in a pivotal multicenter Phase 2 clinical trial under Mustang Bio’s Investigational New Product Drug Application (“IND”) to evaluate MB-107, a lentiviral gene therapy for the treatment of infants under the age of two with XSCID."